#USA #New York #biotechnology #Nanoscope #MOGENRY

Nanoscope Therapeutics to Attend the H.C. Wainwright Global Investment Conference

Nanoscope Therapeutics, Inc., a pioneering biotechnology firm focusing on innovative treatments for retinal disorders, will participate in the upcoming 28th Annual H.C. Wainwright Global Investment Conference. Scheduled to take place from September 14-16, 2026, at the Lotte New York Palace Hotel, this prestigious event draws together key players in the investment community dedicated to advancing healthcare technologies.

Presentation Highlights

The conference will feature a key presentation delivered by Sulagna Bhattacharya, the Chief Executive Officer of Nanoscope Therapeutics. Bhattacharya's presentation is set for Monday, September 14, 2026, at 1:00 PM ET. Attendees can expect insights into the company's latest advancements in optogenetic therapies, particularly its groundbreaking product, MOGENRY (sonpiretigene isteparvovec; MCO-010). This innovative therapy aims to restore vision in patients suffering from diseases associated with photoreceptor loss.

Members of Nanoscope's management team will also be accessible for one-on-one discussions with investors throughout the conference, providing an opportunity for more personalized engagement and inquiries regarding their scientific initiatives and business strategies. Investors interested in these meetings are encouraged to reach out to representatives from H.C. Wainwright or contact Nanoscope directly.

About MOGENRY and Its Impact

MOGENRY stands out as a novel optogenetic gene therapy designed to address retinal degenerations without the complications often associated with traditional treatments. Utilizing a proprietary genetically engineered synthetic opsin, the therapy enhances light sensitivity and encourages the remaining visual circuitry to operate correctly in patients who have experienced photoreceptor loss. Unique to MOGENRY is its ability to forego genetic testing and invasive surgery, making it a straightforward intervention suitable for routine clinical settings.

The company has seen promising results from the RESTORE Phase 2b/3 trials, leading to the acceptance of their Biologics License Application (BLA) by the FDA. MOGENRY holds the potential to set a new standard of care for patients suffering from retinal diseases, particularly retinitis pigmentosa (RP). The therapy is poised to gain traction for its ease of administration as a one-time, in-office injection.

Additionally, Nanoscope is making strides with MCO-010 in the realm of Stargardt disease (SD), having initiated a Phase 2 trial demonstrating encouraging outcomes. With plans for a Phase 3 registrational trial underway targeting Stargardt disease in 2026, their commitment to tackling various retinal disorders is clear. Regulatory accolades, including FDA Fast Track and Orphan Drug designations, further solidify MOGENRY's role within the evolving landscape of vision restoration therapies.

Nanoscope's Vision for the Future

The future looks bright for Nanoscope Therapeutics as they continue to innovate in the field of optogenetics. Their goal is not only to advance MOGENRY but also to explore broader applications of their technology in other retinal degenerative conditions. The success of their clinical programs in the U.S. is being mirrored in international markets with actions taken in countries like Japan and Saudi Arabia, where they have received similar Orphan designations for inherited retinal dystrophies.

With their proactive approach to treatment development, Nanoscope stands as a beacon of hope for millions affected by retinal degeneration across the globe. The participation at the H.C. Wainwright Conference will undoubtedly amplify their reach and foster valuable partnerships driving forward this vital medical research.

For more information about Nanoscope Therapeutics and to stay updated on their latest innovations and conference insights, visit their website or contact their investor relations department.

Contact:
Nanoscope Therapeutics, Inc.
Phone: (817) 857-1186
Email: [email protected]